Notice Regarding Consolidated Subsidiary (MEDLEAP PHARMA COMPANY LIMITED) Notice Regarding the Initiation of Phase 2 Clinical Trial in Japan for Ferri11/14TDnetPDF(402KB)
Notice Regarding Recording of Non-Operating Income and Notice Regarding Recording of Gain on Sales of Investment Securities (Extraordinary Income) Par11/14TDnetPDF(152KB)
Notice Regarding Revision of Consolidated Financial Forecasts for Fiscal Year 202511/14TDnetPDF(104KB)
Consolidated Financial Statements for the Second Quarter of the Fiscal Year Ending March 31, 2026 [Japanese GAAP]11/14TDnetPDF(409KB)
Consolidated Financial Statements for the First Quarter of the Fiscal Year Ending March 31, 2026 [Japanese GAAP]8/6TDnetPDF(660KB)
Notice Regarding Recording of Gain on Sale of Investment Securities (Extraordinary Income)7/28TDnetPDF(123KB)
[Summary]Notice Regarding Completion of Payment for Disposal of Treasury Stockas Restricted Stock and Partial Forfeiture7/25TDnetPDF(230KB)
[Updated]Notice Regarding Disposition of Treasury Stock for Performance-Linked Restricted Stock Compensation7/1TDnetPDF(219KB)
[Summary]Notice Regarding Disposition of Treasury Stock for Performance-Linked Restricted Stock Compensation6/26TDnetPDF(230KB)